Perceptive Advisors Llc Purchases 67,222 Shares of Athenex Inc (NASDAQ:ATNX) Stock

Share on StockTwits

Athenex Inc (NASDAQ:ATNX) major shareholder Perceptive Advisors Llc acquired 67,222 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was bought at an average price of $10.29 per share, with a total value of $691,714.38. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Perceptive Advisors Llc also recently made the following trade(s):

  • On Monday, September 16th, Perceptive Advisors Llc acquired 30,000 shares of Athenex stock. The stock was bought at an average price of $13.58 per share, with a total value of $407,400.00.
  • On Thursday, September 12th, Perceptive Advisors Llc acquired 13,584 shares of Athenex stock. The stock was bought at an average price of $14.05 per share, with a total value of $190,855.20.
  • On Thursday, August 15th, Perceptive Advisors Llc acquired 30,000 shares of Athenex stock. The stock was bought at an average price of $15.00 per share, with a total value of $450,000.00.

Shares of Athenex stock opened at $10.23 on Friday. The firm has a fifty day moving average of $13.03 and a two-hundred day moving average of $14.78. The stock has a market capitalization of $834.57 million, a price-to-earnings ratio of -7.10 and a beta of -0.21. Athenex Inc has a 52 week low of $9.38 and a 52 week high of $21.11. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.33 and a current ratio of 2.62.

Athenex (NASDAQ:ATNX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.44) EPS for the quarter, meeting the consensus estimate of ($0.44). The company had revenue of $22.20 million during the quarter, compared to analysts’ expectations of $18.15 million. Athenex had a negative net margin of 161.17% and a negative return on equity of 85.39%. As a group, research analysts forecast that Athenex Inc will post -1.96 EPS for the current fiscal year.

Several research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Athenex from a “hold” rating to a “sell” rating in a research report on Tuesday, July 9th. SunTrust Banks boosted their price objective on shares of Athenex to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. They noted that the move was a valuation call. BidaskClub cut shares of Athenex from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 10th. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 price objective (up previously from $29.00) on shares of Athenex in a research report on Tuesday, June 25th. Finally, ValuEngine upgraded shares of Athenex from a “hold” rating to a “buy” rating in a research report on Thursday, October 10th. Two investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $23.83.

Several institutional investors have recently modified their holdings of the business. Cambiar Investors LLC bought a new stake in shares of Athenex during the 3rd quarter valued at $917,000. Orbimed Advisors LLC raised its position in shares of Athenex by 793.1% during the 2nd quarter. Orbimed Advisors LLC now owns 3,840,130 shares of the company’s stock valued at $76,035,000 after acquiring an additional 3,410,130 shares during the last quarter. Perceptive Advisors LLC raised its position in shares of Athenex by 92.7% during the 2nd quarter. Perceptive Advisors LLC now owns 9,822,118 shares of the company’s stock valued at $187,636,000 after acquiring an additional 4,726,096 shares during the last quarter. Royal Bank of Canada raised its position in shares of Athenex by 24.4% during the 2nd quarter. Royal Bank of Canada now owns 102,642 shares of the company’s stock valued at $2,033,000 after acquiring an additional 20,137 shares during the last quarter. Finally, Eaton Vance Management bought a new stake in shares of Athenex during the 2nd quarter valued at $238,000. Institutional investors own 48.31% of the company’s stock.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.

Featured Article: Blockchain

Insider Buying and Selling by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AT&T Inc.  Stake Lifted by Doyle Wealth Management
AT&T Inc. Stake Lifted by Doyle Wealth Management
Oracle Co.  Shares Sold by Doyle Wealth Management
Oracle Co. Shares Sold by Doyle Wealth Management
Doyle Wealth Management Buys 1,216 Shares of Vanguard Real Estate ETF
Doyle Wealth Management Buys 1,216 Shares of Vanguard Real Estate ETF
Visa Inc  Shares Bought by Doyle Wealth Management
Visa Inc Shares Bought by Doyle Wealth Management
Critical Contrast: Franchise Group  and Service Co. International
Critical Contrast: Franchise Group and Service Co. International
Medtronic PLC  Shares Sold by Doyle Wealth Management
Medtronic PLC Shares Sold by Doyle Wealth Management


 
© 2006-2019 Zolmax.